Print Page | Contact Us | Report Abuse | Sign In | Register
Data Collection Requirements
Share |

As agreed to in the MOA with FADAA, providers are required to submit monthly program reports via a web-based data reporting and analysis system (data portal). The required data is aggregated by FADAA, submitted to OSCA and DCF, and will serve as documentation for continued funding.  Providers must assign each patient a unique, de-identified client number for reporting purposes.

Required Data Elements Are:

1. Monthly medication inventory reports for Vivitrol® including number of doses on hand at the beginning of each month (-) less the number administered (+) plus the number received from the designated specialty pharmacy (=) equals the number of doses on hand at the end of the month;

2. Monthly client data program activity and outcomes. Data will include, but may not be limited to:

  •  Number of clients screened and educated on the use, benefits, and risks of extended-release injectable naltrexone;
  •  Number of clients assessed (received physical exam and/or lab work) for use of extended-release injectable naltrexone;
  •  Number of clients who received one or more doses of extended-release injectable naltrexone;
  •  Number of clients screened, educated, and/or assessed who did not receive one or more doses of extended-release injectable naltrexone and reason for not receiving

3. At the provider level only: Demographics of individuals served (first, middle, and last name; date of birth; race; ethnicity; gender; social security number; state identification number; Florida Department of Corrections number, if applicable; county with court jurisdiction of case; current charge(s); court case number; type of problem-solving court, if applicable; alcohol or opioid as drug of choice; and current treatment modality, including outpatient, inpatient, and/or aftercare. This data must be aggregated by the provider before it is submitted to FADAA.

4. Client outcomes including, urge to drink and/or use opiates; number days in the month that client drank or used opiates; number of admissions to inpatient treatment; number of days client participated in treatment (treatment retention); increase or decrease in observed or reported symptoms; and changes in social and occupational functioning.

5. Number of clients who received at least one dose of extended-release injectable naltrexone and completed the prescribed course of treatment with the total number of doses received by client.

6. Number of clients who received at least one dose of extended-release injectable naltrexone and did not complete the prescribed course of treatment with the total number of doses received by client.

7. Average number of doses for alcohol users and average number of doses for opioid users

8. The annual number of offender treatment referrals you anticipate receiving from the local court system and an estimate of the projected number of these individuals who would be appropriate for medication-assisted treatment using Vivitrol®.